International Stem Cell Corporation is Valued at Over 400% of Its Current Market Value by Edison Investment Research
September 13 2017 - 8:30AM
InvestorsHub NewsWire
CARLSBAD, CA -- September 13, 2017 -- InvestorsHub NewsWire --
International Stem Cell Corporation (OTCQB:ISCO)
("ISCO" or "the Company"), a California-based clinical stage
biotechnology company developing novel stem cell-based therapies
and biomedical products, announced today that it has been valued at
$27 million or $6.62 per basic share by Edison Investment Research
(“Edison”), a world-renowned investment intelligence firm with more
than one hundred analysts, investment experts, and roadshow
professionals, based in offices in London, New York, Frankfurt,
Sydney, and Wellington. The research report is available on
Edison’s website and can be accessed here. The report features an
analysis of ISCO’s financial data, along with an investment summary
that showcases the company’s cell therapy for Parkinson’s disease
and Traumatic Brain Injury as a key industry differentiator.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and
cosmetic products. ISCO's core technology, parthenogenesis, results
in the creation of pluripotent human stem cells from unfertilized
oocytes (eggs). hpSCs avoid ethical issues associated with the use
or destruction of viable human embryos. ISCO scientists have
created the first parthenogenetic, homozygous stem cell line that
can be a source of therapeutic cells for hundreds of millions of
individuals of differing genders, ages and racial background with
minimal immune rejection after transplantation. hpSCs offer the
potential to create the first true stem cell bank, UniStemCell™.
ISCO also produces and markets specialized cells and growth media
for therapeutic research worldwide through its subsidiary Lifeline
Cell Technology (www.lifelinecelltech.com),
and stem cell-based skin care products through its subsidiary
Lifeline Skin Care (www.lifelineskincare.com).
More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please
click - http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our us on Facebook page or follow us on
Twitter for company updates and industry related news,
visit: www.facebook.com/InternationalStemCellCorporation
and twitter.com/russakern
Safe harbor statement
Statements pertaining to anticipated developments, expected
pre-clinical studies (including timing and results), progress of
research and development, and other opportunities for the company
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates,") should also be considered
to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of
potential products, regulatory approvals, need and ability to
obtain future capital, application of capital resources among
competing uses, and maintenance of intellectual property rights.
Actual results may differ materially from the results anticipated
in these forward-looking statements and as such should be evaluated
together with the many uncertainties that affect the company's
business, particularly those mentioned in the cautionary statements
found in the company's Securities and Exchange Commission filings.
The company disclaims any intent or obligation to update
forward-looking statements.
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Sep 2024 to Oct 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Oct 2023 to Oct 2024